Literature DB >> 12818205

Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.

Sergey M Kipriyanov1, Gerhard Moldenhauer, Michael Braunagel, Uwe Reusch, Björn Cochlovius, Fabrice Le Gall, Olga A Kouprianova, Claus Wilhelm Von der Lieth, Melvyn Little.   

Abstract

Bispecific single-chain Fv antibodies comprise four covalently linked immunoglobulin variable (VH and VL) domains of two different specificities. Depending on the order of the VH and VL domains and on the length of peptides separating them, the single-chain molecule either forms two single-chain Fv (scFv) modules from the adjacent domains of the same specificity, a so-called scFv-scFv tandem [(scFv)(2)], or folds head-to-tail with the formation of a diabody-like structure, a so-called bispecific single-chain diabody (scBsDb). We generated a number of four-domain constructs composed of the same VH and VL domains specific either for human CD19 or CD3, but arranged in different orders. When expressed in bacteria, all (scFv)(2) variants appeared to be only half-functional, binding to CD19 and demonstrating no CD3-binding activity. Only the diabody-like scBsDb could bind both antigens. Comparison of the scBsDb with a structurally similar non-covalent dimer (diabody) demonstrated a stabilizing effect of the linker in the middle of the scBsDb molecule. We demonstrated that the mechanism of inactivation of CD19xCD3 diabody under physiological conditions is initiated by a dissociation of the weaker (anti-CD3) VH/VL interface followed by domain swapping with the formation of non-active homodimers. The instability of one homodimer makes the process of diabody dissociation/reassociation irreversible, thus gradually decreasing the fraction of active molecules. The structural parameters influencing the formation of functional bispecific single-chain antibodies are indicated and ways of making relatively stable bispecific molecules are proposed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818205     DOI: 10.1016/s0022-2836(03)00526-6

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  16 in total

1.  Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Yukiko Sone; Hiroko Kawaguchi; Shintaro Taki; Hiroki Hayashi; Takeshi Nakanishi; Mitsuo Umetsu; Yu Katayose; Michiaki Unno; Toshio Kudo; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

2.  Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Ippei Shimomura; Shintaro Taki; Takeshi Nakanishi; Mitsuo Umetsu; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

3.  Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.

Authors:  Bryan D Choi; Patrick C Gedeon; Chien-Tsun Kuan; Luis Sanchez-Perez; Gary E Archer; Darell D Bigner; John H Sampson
Journal:  J Immunol Methods       Date:  2013-06-24       Impact factor: 2.303

4.  A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.

Authors:  Patrick C Gedeon; Teilo H Schaller; Satish K Chitneni; Bryan D Choi; Chien-Tsun Kuan; Carter M Suryadevara; David J Snyder; Robert J Schmittling; Scott E Szafranski; Xiuyu Cui; Patrick N Healy; James E Herndon; Roger E McLendon; Stephen T Keir; Gary E Archer; Elizabeth A Reap; Luis Sanchez-Perez; Darell D Bigner; John H Sampson
Journal:  Clin Cancer Res       Date:  2018-04-27       Impact factor: 12.531

5.  The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics.

Authors:  Sami El Khatib; Mohamed Salla
Journal:  Leuk Res Rep       Date:  2022-06-27

6.  Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing.

Authors:  Ludger Grosse-Hovest; Sigrid Müller; Rosa Minoia; Eckhard Wolf; Valeri Zakhartchenko; Hendrik Wenigerkind; Caroline Lassnig; Urban Besenfelder; Mathias Müller; Simon D Lytton; Gundram Jung; Gottfried Brem
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-22       Impact factor: 11.205

Review 7.  An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.

Authors:  Patrick C Gedeon; Bryan D Choi; Tiffany R Hodges; Duane A Mitchell; Darell D Bigner; John H Sampson
Journal:  Expert Rev Clin Pharmacol       Date:  2013-07       Impact factor: 5.045

8.  Bispecific antibodies targeting mutant RAS neoantigens.

Authors:  Jacqueline Douglass; Emily Han-Chung Hsiue; Brian J Mog; Michael S Hwang; Sarah R DiNapoli; Alexander H Pearlman; Michelle S Miller; Katharine M Wright; P Aitana Azurmendi; Qing Wang; Suman Paul; Annika Schaefer; Andrew D Skora; Marco Dal Molin; Maximilian F Konig; Qiang Liu; Evangeline Watson; Yana Li; Michael B Murphy; Drew M Pardoll; Chetan Bettegowda; Nickolas Papadopoulos; Sandra B Gabelli; Kenneth W Kinzler; Bert Vogelstein; Shibin Zhou
Journal:  Sci Immunol       Date:  2021-03-01

9.  An engineered genetic selection for ternary protein complexes inspired by a natural three-component hitchhiker mechanism.

Authors:  Hyeon-Cheol Lee; Alyse D Portnoff; Mark A Rocco; Matthew P DeLisa
Journal:  Sci Rep       Date:  2014-12-22       Impact factor: 4.379

10.  Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.

Authors:  Yiren Xu; John Lee; Cuong Tran; Tyler H Heibeck; Willie D Wang; Junhao Yang; Ryan L Stafford; Alexander R Steiner; Aaron K Sato; Trevor J Hallam; Gang Yin
Journal:  MAbs       Date:  2015       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.